XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net loss $ (282,809) $ (191,008)
Adjustments to reconcile net loss to cash provided by operating activities:    
Depreciation and amortization 207,449 200,430
Net amortization of debt discounts, premiums and issuance costs 76,642 6,616
Straight line rental income (1,605) 1,333
Amortization of acquired real estate leases and other intangible assets, net 84 (264)
Loss on modification or early extinguishment of debt 209 1,075
Impairment of assets 41,718 18,380
Loss (gain) on sale of properties 18,976 (1,233)
Gains on equity securities, net 0 (8,126)
Other non-cash adjustments, net (405) (1,328)
Unconsolidated joint venture distributions 1,231 3,870
Equity in net losses (earnings) of investees 9,882 (2,137)
Change in assets and liabilities:    
Deferred leasing costs, net (2,199) (7,995)
Other assets 2,828 4,315
Accrued interest (258) 2,628
Other liabilities 22,285 (8,864)
Net cash provided by operating activities 94,028 17,692
Cash flows from investing activities:    
Real estate improvements (134,966) (168,400)
Proceeds from sale of properties, net 27,845 3,548
Investment in AlerisLife Inc. (15,459) 0
Proceeds from insurance recoveries 1,698 0
Proceeds from AlerisLife Inc. tender offer 0 14,006
Net cash used in investing activities (120,882) (150,846)
Cash flows from financing activities:    
Proceeds from mortgage notes payable 120,000 0
Repayments of borrowings on credit facility 0 (250,000)
Redemption of senior unsecured notes (60,000) 0
Repayment of other debt (2,388) (16,408)
Payment of debt issuance costs (8,203) (2,057)
Repurchase of common shares (902) (386)
Distributions to shareholders (7,214) (7,192)
Net cash provided by (used in) financing activities 41,293 (276,043)
Increase (decrease) in cash and cash equivalents and restricted cash 14,439 (409,197)
Cash and cash equivalents and restricted cash at beginning of period 246,961 688,302
Cash and cash equivalents and restricted cash at end of period $ 261,400 $ 279,105